Denmark-based Xellia Pharmaceuticals has announced its plans to invest US$100 million in the expansion of its manufacturing plant located at 8900 Capital Boulevard in the City of Raleigh.
Retaining 90 existing jobs, the company also plans to create 40 permanent full-time jobs over next five years with average annual salaries to range from US$45,000 to US$70,000. The company plans to hire wide spectrum of roles from manufacturing technicians and maintenance mechanics to senior quality control and assurance, validation and technology transfer specialists.
Along with Xelloa’s investment of US$100 million, the Wake County Board of Commissioners approved a US$1.05 million business investment grant for expanding the company’s manufacturing operations in north Raleigh. Beside this, Raleigh City Council also promised an economic development incentive valued around US$280,000 over a five-year period.
The company will combine the incentive from the City of Raleigh with its own investment for the expansion process.
In Raleigh facility, the company plans to manufacture lyophilized, or freeze-dried, vial drugs for anti-infective treatments.
The company has acquired this 84,687-square-foot manufacturing facility run by Fresenius Kabi in July for US$7.5 million.
